Following the launch of the first disease-modifying therapies for Alzheimer’s disease, a key theme at the AD/PD 2025 ...

Rhythm's Imcivree has shown benefit in a Phase III trial in patients with acquired hypothalamic obesity, leading to 19.8% ...

RFK Jr supported the MMR vaccine’s efficacy in preventing measles, but also shared unproven treatment strategies.

The European Commission (EC) has granted approval for AstraZeneca's Imfinzi plus chemotherapy for treating resectable NSCLC ...

China’s NMPA has granted approval for the marketing authorisation application of Santen Pharmaceutical's Tapcom.

ABL Bio has announced a global licensing agreement with GSK, allowing the latter to develop medicines for neurodegenerative ...

The CMS has opted not to move forward with a plan that would have extended Medicare coverage to obesity drugs for millions of ...

Neurona will kick start a Phase III trial in H2 2025 investigating NRTX-1001 in patients with a type of drug-resistant ...

Sanofi's oral, reversible Bruton’s tyrosine kinase (BTK) inhibitor rilzabrutinib has gained US Food and Drug Administration ...

According to a factsheet published by the Trump administration, pharmaceuticals are exempted from the tariffs – for now.

With an increasing demand for NHS services, technology is being positioned as a critical tool in eliminating inefficiencies ...

Abrysvo is now approved in the EU for adults aged 18 to 59 who are at increased risk of lower respiratory tract disease ...